Enliven Therapeutics, Inc. (ELVN) Stock

Enliven Therapeutics, Inc. (ELVN) is a Healthcare stock trading at $45.13 (as of 2026-06-18), with a market capitalization of $2.41B and a trailing P/E of -27.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule inhibitors for cancer. Its pipeline includes ELVN-001, a Phase 1 study in adults with chronic myeloid leukemia, and ELVN-002, a Phase 1 trial for cancers with abnormal HER2 gene activity.

Valuation — source: SEC EDGAR (first-party)
Price$45.13
Market Cap$2.41B
P/E Ratio-27.5
EV / EBITDA-22.6
Price / Book6.06
DCF Value (model)$-18.40
DCF Upside vs Price-140.8%
Profitability & Growth — source: SEC EDGAR
Return on Equity-21.8%
Current Ratio40.32
Valuation vs Sector & Industry
Stock P/E-27.5
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-231.2%
vs Industry-259.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderORBIMED ADVISORS LLC ($312.01M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORichard A. Fair
Employees62
CountryUS
IPO Date2020-03-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Compass Therapeutics, Inc. (CMPX)
  • Bicara Therapeutics Inc. Common Stock (BCAX)
  • OPKO Health, Inc. (OPK)
  • Arbutus Biopharma Corporation (ABUS)
  • CorMedix Inc. (CRMD)
  • Kura Oncology, Inc. (KURA)
  • Nektar Therapeutics (NKTR)
  • ArriVent BioPharma, Inc. Common Stock (AVBP)
ELVN earnings history · ELVN institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.